Europe’s VC Retreat May Threaten Drug Innovation There
This article was originally published in The Pink Sheet Daily
Executive Summary
The number of VC firms actively investing in European biotech and life science companies - and the funds available for investing - could fall below the critical mass considered vital for supporting innovation, investors warn.